STAT+: ‘We don’t agree’ on drug pricing policy, FDA chief tells biotech leaders
At the BIO convention, the FDA chief asks, “How can it be that we're creating all this stuff that the rest of the world uses, and they're doing so much…
BOSTON — The drug industry has spent the past year speaking against new mechanisms that could limit how much governments or insurers pay for certain new medicines. Robert Califf, the Food and Drug Administration chief, walked on stage Wednesday and told a crowd of biotech leaders that drug costs needed fixing.
“We don’t agree,” said Califf, referring to a conversation he had backstage with Ted Love, the new chair of the Biotechnology Innovation Organization. “I think the prices of drugs are too high in the U.S.”
Califf has an apparent habit of walking into industry meetings and saying precisely what that industry doesn’t want to hear. He also spent much of his career working on new ways of generating decisive evidence for therapies and other medical interventions.
What's Your Reaction?
